Winslow Evans & Crocker’s BioNTech BNTX Stock Holding History

Winslow Evans & Crocker’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$41K	Hold	500	–	–	0.01%	640
2020 Q3	$35K	Buy	+500	New	+$35.9K	0.01%	521

Other funds holding BNTX

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Winslow Evans & Crocker's BNTX Position: Q4 2020 in Review

Winslow Evans & Crocker held its BioNTech (BNTX) position steady in Q4 2020 at 500 shares worth $41K. The position accounts for 0.01% of the portfolio, ranked #640.

Winslow Evans & Crocker first reported a position in BNTX in Q3 2020 and has held it in 2 quarters since. 194 funds tracked by Wall St. Rank hold BNTX as of Q4 2020.

Winslow Evans & Crocker held 500 shares of BioNTech worth $41K as of Q4 2020.
Winslow Evans & Crocker left its BioNTech share count unchanged in Q4 2020.
BioNTech made up 0.01% of Winslow Evans & Crocker's portfolio in Q4 2020, its #640 holding.
Winslow Evans & Crocker first reported a position in BioNTech in Q3 2020 and has held it in 2 quarters since.
194 funds tracked by Wall St. Rank held BioNTech as of Q4 2020.

Based on Winslow Evans & Crocker's 13F filing for Q4 2020, filed 3 Feb 2021.